Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan

References

• Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J. Hum. Hypertens.18, 545–551 (2004).
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA290, 199–206 (2003).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet365, 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Deitel M. Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes. Surg.13, 329–330 (2003).
   PubMed Web of Science ®Google Scholar
• Klein S, Burke LE, Bray GA et al. Clinical implications of obesity with specific forms on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation110, 2952–2967 (2004).
   PubMed Web of Science ®Google Scholar
• Bogers RP, Bemelmans WJ, Hoogenveen RT et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels. A meta-analysis of 21 cohort studies including more than 300 000 persons. Arch. Intern. Med.167, 1720–1728 (2007).
   PubMed Web of Science ®Google Scholar
• Felber JP, Golay A. Pathway from obesity to diabetes. Int. J. Obes.26, S39–S45 (2002).
   PubMed Web of Science ®Google Scholar
• Eckel RH, Kahn R, Robertson RM et al. Preventing cardiovascular disease and diabetes: A call to action from the American Diabetes Association and the American Heart Association. Diabetes Care29, 1697–1699 (2006).
   PubMed Web of Science ®Google Scholar
• Klein S, Allison DB, Heymsfield SB et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care30, 1647–1652 (2007).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al. For the INTERHEART study investigators. Obesity and the risk of myocardical infarction in 27000 participants from 52 countries: a case–control study. Lancet366, 1640–1649 (2005).
   PubMed Web of Science ®Google Scholar
• Stas S, Appesh L, Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr. Hypertens. Rep.8, 403–408 (2006).
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature444, 881–887 (2006).
   PubMed Web of Science ®Google Scholar
• Reaven GM. Role of insulin resistance in human disease. Diabetes37, 1595–1607 (1988).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Coordinating Committee of the National Cholesterol Education Program.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol.44, 720–732 (2004).
   PubMed Web of Science ®Google Scholar
• Kahn R, Buse J, Ferrannini E et al. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care28, 2289–2304 (2005).
   PubMed Web of Science ®Google Scholar
• Redon J, Cífková R. The metabolic syndrome in hypertension: diagnostic and therapeutic implications. Curr. Hypertens. Rep.9, 305–313 (2007).
   PubMed Web of Science ®Google Scholar
• Hall J, Whelton PK, Appel LJ et al. Long-term effects of weight loss and dietary sodium restriction on incidence of hypertension Hypertension35, 544–549 (2000).
   PubMed Web of Science ®Google Scholar
• Haynes WG, Morgan DA, Walsh SA et al. Receptor- mediated sympathetic nerve activation by leptin. J. Clin. Invest.100, 270–278 (1997).
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Haynes WG, Morgan DA et al. Selective resistance to central neural administration of leptin in agout obese mice. Hypertension39, 486–490 (2003).
   Web of Science ®Google Scholar
• Eikelis N, Schlaich M, Aggarwel A et al. Interaction between leptin and the human sympathetic nervous system. Hypertension41, 1072–1079 (2003).
   PubMed Web of Science ®Google Scholar
• Umemura S, Nyui N, Tamura K et al. Plasma angiotensinogen concentrations in obese patients. Am. J. Hypertens.10, 629–633 (1997).
   PubMed Web of Science ®Google Scholar
• Cassis LA. Fat cell metabolism: insulin, fatty acids and renin. Curr. Hypertens. Rep.2, 132–138. (2000).
   PubMedGoogle Scholar
• Schorr U, Blaschke K, Distler TS, Sharma AM: Relationship between angiotensinogen, leptin and blood pressure in young normotensive men. J. Hypertens.16, 1475–1480 (1998).
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Correia MLG, Haynes WG et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension45, 9–14 (2005).
   PubMed Web of Science ®Google Scholar
• Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann. NY Acad. Sci.892, 91–107 (1999).
   PubMed Web of Science ®Google Scholar
• Reisin E, Weir MR, Falkner B et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension30, 140–145 (1997).
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep-apnea, and aldosterone: theory and therapy. Hypertension43, 518–524 (2004).
   PubMed Web of Science ®Google Scholar
• Ehrhart-Bornstein M, Lamounier-Zepter V, Shraven A et al. Human adipocytes secrete mineralocorticoid – releasing factors. Proc. Natl Acad. Sci. USA100, 14211–1426 (2003).
   PubMed Web of Science ®Google Scholar
• de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hypertension Hypertension43, 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Hall JE. The kidney, hypertension and obesity. Hypertension41, 625–633 (2003).
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism39, 167–174 (1990).
   PubMed Web of Science ®Google Scholar
• Fournier AM, Gadia MT, Kubrusly DB et al. Blood pressure, insulin, and glycemia in nondiabetic subjects. Am. J. Med.80, 861–864 (1986).
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Natali A, Capaldo B et al. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance. Hypertension30(5), 1144–1149 (1997).
   PubMed Web of Science ®Google Scholar
• Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J. Hypertens.9, 217–223 (1991).
   PubMed Web of Science ®Google Scholar
• Alvarez GE, Beske SD, Ballard TP et al. Sympathetic neural activation in visceral obesity. Circulation106, 2533–2536 (2002).
   PubMed Web of Science ®Google Scholar
• de Vriese AS, Verbeuren TJ, Van de Voorde J et al. Endothelial dysfunction in diabetes. Br. J. Pharmacol.130, 963–974 (2000).
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun.257, 79–88 (1999).
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol.20, 1595–1599 (2000).
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation100, 2473–2476 (1999).
   PubMed Web of Science ®Google Scholar
• Kazumi T, Kawaguchi A, Sakai K et al. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL, size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care25, 971–976 (2002).
   PubMed Web of Science ®Google Scholar
• Patel DA, Srinivasan SR, Xu JH et al. Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism55, 1551–1557 (2006).
   PubMed Web of Science ®Google Scholar
• Francischetti EA, Celoria BMJ, Duarte SFP et al. Hypoadiponectinemia is associated with blood pressure increase in obese insulin-resistant individuals. Metabolism56, 1464–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med.342, 905–912 (2000).
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Blaufox MD, Oberman AS et al. The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild Hypertension Arch. Intern. Med.152, 131–136 (1992).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346, 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med.336, 1117–1124 (1997).
   PubMed Web of Science ®Google Scholar
• Whelton SP, Chin A, Xin X et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann. Intern. Med.136, 493–503 (2002).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG et al. Finnish Diabetes Prevention Study Group. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med.344, 1343–1350 (2001).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care26, S80–S82 (2003).
   Google Scholar
• Goldner MG, Zarowitz H, Akgun S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N. Engl. J. Med.262, 403–405 (1960).
   PubMed Web of Science ®Google Scholar
• Murphy MB, Lewis PJ, Kohner E et al. Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet2, 1293–1305 (1982).
   PubMed Web of Science ®Google Scholar
• Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA286, 1945–1948 (2001).
   PubMed Web of Science ®Google Scholar
• Padwal R, Majumdar SR, Johnson JA et al. A systematic review of drug therapy to delay or prevent Type 2 diabetes. Diabetes Care28, 736–744 (2005).
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J. Hypertens.24, 3–10 (2006).
   PubMed Web of Science ®Google Scholar
• Wing LMH, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med.348, 583–592 (2003).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Kartman B, Carlberg B et al. Cost implications of development of diabetes in the ALPINE study. J. Hypertens.24, S65–S72 (2006).
   Google Scholar
• Mancia G, Brown M, Castaigne A et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension4, 431–436 (2003)
   Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA288, 2981–2997 (2002).
   Google Scholar
• Barzilay JI, Davis BR, Cutler JA et al; for the ALLHAT Collaborative Research Group. Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.166, 2191–2201 (2006).
   PubMed Web of Science ®Google Scholar
• Whelton PK, Barzilay J, Cushman WC et al; for the ALLHAT Collaborative Research Group. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.165, 1401–1409 (2005).
   PubMed Web of Science ®Google Scholar
• Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH et al. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf.24, 443–456 (2001).
   PubMed Web of Science ®Google Scholar
• Lakshman MR, Reda DJ, Materson BJ et al. Diuretics and β-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with Hypertension Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch. Intern. Med.159, 551–558 (1999).
   PubMed Web of Science ®Google Scholar
• Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ304, 405–412 (1992).
   Google Scholar
• Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet36, 895–906 (2005).
   Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should b blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet366, 1545–1553 (2005).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Bakris GL. Antihypertensive therapy and the risk of Type 2 diabetes mellitus. N. Engl. J. Med.342, 969–70 (2000).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet370, 591–603 (2007).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA292, 2227–2236 (2004).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic Hypertension The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet350, 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Renin–angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab.30, 498–505 (2004).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol.91, 30–37 (2003).
   PubMed Web of Science ®Google Scholar
• Blendea MC, Jacobs D, Stump CS et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am. J. Physiol. Endocrinol. Metab.288, 353–359 (2005).
   PubMed Web of Science ®Google Scholar
• Sharma AM, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J. Cardiometab. Syndr.1, 29–35 (2006).
   PubMedGoogle Scholar
• Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension42, 76–81 (2003).
   PubMed Web of Science ®Google Scholar
• Di Filippo C, Lampa E, Tufariello E et al. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes. Res.13, 1909–1914 (2005).
   PubMedGoogle Scholar
• Abuissa H, Jones PG, Marso SP et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol.46, 821–826 (2005).
   PubMed Web of Science ®Google Scholar
• Gillespie EL, White CM, Kardas M et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset Type 2 diabetes. Diabetes Care28, 2261–2266 (2005).
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm KA, Tikellis C, Reid CM et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens.23, 463–473 (2005).
   PubMed Web of Science ®Google Scholar
• Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369, 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Thornley-Brown D, Wang X, Wright JT Jr et al. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch. Intern. Med.166, 797–805 (2006).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Ostergren JB, Gerstein HC et al. Effects of candesartan on the development of a new diagnosis of diabetes in patients with heart failure. Circulation112, 48–53 (2005).
   PubMed Web of Science ®Google Scholar
• Fletcher A, Amery A, Birkenhager W et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J. Hypertens.9, 225–30 (1991).
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Liu G et al. for the FEVER Study Group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens.23, 2157–2172 (2005).
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Berglund G, Elmfeldt D et al. β-blockers versus diuretics in hypertensive men: main result from the HAPPHY trial. J. Hypertens.5, 560–572 (1987).
   Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA290, 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P et al, for the the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet356, 359–365 (2000).
   PubMed Web of Science ®Google Scholar
• The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351, 2058–2068 (2004).
   Google Scholar
• Hansson L, Lindholm LH, Ekbom T et al, for the STOP Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet354, 751–756 (1999).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Wilson AC, Freudenberger RS et al. SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am. J. Cardiol.95, 29–35 (2005).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen S E, Weber M et al, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med.355, 1551–1562 (2006).
   Google Scholar
• Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet353, 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Gerstein H, Hoogwerf B et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA286, 1882–1885 (2001).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux, RB, Kjeldsen, SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21, 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J. Renin Angiotensin Aldosterone Syst.7, 61–73 (2006).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension43, 963–969 (2004).
   PubMed Web of Science ®Google Scholar
• Qiao Q, Jousilahti P, Eriksson J et al. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care26, 2910–2914 (2003).
   PubMed Web of Science ®Google Scholar
• Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs66, 51–83 (2006).
   PubMed Web of Science ®Google Scholar
• Kakuta H, Sudoh K, Sasamata M et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int. J. Clin. Pharmacol. Res.25, 41–46 (2005).
   PubMedGoogle Scholar
• Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs61, 1501–1529 (2001).
   PubMed Web of Science ®Google Scholar
• Goebel M, Clemenz M, Unger T. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. Expert Rev. Cardiovasc. Ther.4, 615–629 (2006).
   PubMedGoogle Scholar
• Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol.4, 6 (2005).
   Google Scholar
• Koulouris S, Symeonides P, Triantafyllou K et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with Type 2 diabetes mellitus. Am. J. Cardiol.95, 1386–1398 (2005).
   PubMed Web of Science ®Google Scholar
• Derosa G, Ragonesi PD, Mugellini A et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, Type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res.27, 457–464 (2004).
   PubMed Web of Science ®Google Scholar
• Benndorf RA, Rudolph T, Appel D et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism55, 1159–1164 (2006).
   PubMed Web of Science ®Google Scholar
• Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ. Res.96, 1042–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension43, 993–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation109, 2054–2067 (2004).
   PubMed Web of Science ®Google Scholar
• Schupp M, Clemenz M, Gineste R et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes54, 3442–3452 (2005).
   PubMed Web of Science ®Google Scholar
• Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol.42, S9–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Bertone G et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with Type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther.26, 1228–1236 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Burke TA, Krobot K et al. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J. Hum. Hypertens.18, 367–373 (2004).
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J. Hypertens.25, 841–848 (2007).
   PubMed Web of Science ®Google Scholar
• Sharma AM, Davidson J, Koval S et al. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with Type 2 diabetes: the SMOOTH study. Cardiovasc. Diabetol.6, 28 (2007).
   PubMed Web of Science ®Google Scholar
• DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368, 1096–1105 (2006).
   Google Scholar
• Bakris GL. Differences in glucose tolerance between fixed-dose antihypertensive drug combination in people with metabolic syndrome. Diabetes Care30, 24 (2007).
   Google Scholar
• Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia28, 590–596 (1985).
   PubMed Web of Science ®Google Scholar
• Mancia G, Backer GD, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med.329, 1456–1462 (1993).
   PubMed Web of Science ®Google Scholar
• Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive Type II diabetic patients. Ann. Intern. Med.118, 577–581 (1993).
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet355, 253–259 (2000).
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345, 861–869 (2001)
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. The Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.165, 936–946 (2005).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int.61, 1086–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ317, 713–720 (1998).
   Google Scholar
• Ibsen H, Olsen MH, Wachtell K et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care29, 595–600 (2006).
   PubMed Web of Science ®Google Scholar
• Giancarlo Viberti, Nigel M. Wheeldon for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect. Circulation106, 672–678 (2002).
   PubMedGoogle Scholar
• Ruggenenti P, Fassi A, Ilieva AP et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med.351, 1941–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr. Metab.17, 259–66 (2004).
   PubMedGoogle Scholar
• Marre M, Puig J G, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with Type 2 diabetes: The NESTOR* study. J. Hypertens.22, 1613–1622 (2004).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Bain SC, Bouter P et al. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med.351, 1952–1961 (2004).
   PubMed Web of Science ®Google Scholar
• Makino H, Haneda M, Babazono T et al. INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with Type 2 diabetes. Diabetes Care301577–1578 (2007).
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med.345, 870–878 (2001).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and Type 2 diabetes. Diabetes Care30, 1351–1356 (2007).
   PubMed Web of Science ®Google Scholar
• Bakris G, Burgess E, Weir M et al. Comparative long-term effects of two AT1 receptor blockers on proteinuria in patients with Type 2 diabetes and overt nephropathy and hypertension: results of the AMADEO study. American Society of Hypertension 2007 Scientific Sessions. Chicago, IL, USA, 21 May 2007.
   Google Scholar
• Teo K, Yusuf S, Sleight P et al; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart. J.148, 52–61 (2004).
   PubMed Web of Science ®Google Scholar